Ligand Pharmaceuticals Incorporated (LGND) — Cash Flow Quality Index
Ligand Pharmaceuticals Incorporated (LGND) has a Cash Flow Quality Index of 1.02x as of December 2025. Operating cash flow of $45.84 Million exceeds net income of $44.78 Million, indicating high earnings quality where cash backs reported profits. Explore long-term investment intensity of Ligand Pharmaceuticals Incorporated to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Ligand Pharmaceuticals Incorporated Cash Flow Quality Index (2007–2025)
Historical Cash Flow Quality Index for Ligand Pharmaceuticals Incorporated across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible net worth ratio of Ligand Pharmaceuticals Incorporated to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Ligand Pharmaceuticals Incorporated (2007–2025)
Year-by-year earnings quality comparison for Ligand Pharmaceuticals Incorporated. For live market cap and the full company financial profile, see market value of Ligand Pharmaceuticals Incorporated.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.40x | $49.36 Million | $124.45 Million | ▼ -58.3% |
| 2023 | 0.95x | $49.58 Million | $52.15 Million | ▼ -31.1% |
| 2021 | 1.38x | $78.80 Million | $57.14 Million | ▲ +3058.3% |
| 2019 | -0.05x | $-29.34 Million | $629.30 Million | ▼ -103.4% |
| 2018 | 1.35x | $194.06 Million | $143.32 Million | ▼ -81.8% |
| 2017 | 7.45x | $93.57 Million | $12.56 Million | ▲ +4452.7% |
| 2015 | 0.16x | $41.73 Million | $254.93 Million | ▼ -91.3% |
| 2014 | 1.89x | $20.57 Million | $10.89 Million | ▼ -19.4% |
| 2013 | 2.34x | $20.69 Million | $8.83 Million | ▲ +2133.4% |
| 2011 | -0.12x | $-1.17 Million | $10.17 Million | ▲ +66.8% |
| 2007 | -0.35x | $-97.73 Million | $281.69 Million | — |